These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 24861837

  • 1. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial.
    Zhou ZY, Xu L, Li HG, Tian JH, Jiao LJ, You SF, Han ZF, Jiang Y, Guo HR, Liu H.
    J Integr Med; 2014 May; 12(3):175-81. PubMed ID: 24861837
    [Abstract] [Full Text] [Related]

  • 2. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Jiang Y, Liu LS, Shen LP, Liu JX, Jiang GN, Gu AQ, Li HC, Li Q, Li HG, Huang PX.
    Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
    [Abstract] [Full Text] [Related]

  • 3. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
    Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ.
    Complement Ther Med; 2016 Feb; 24():55-62. PubMed ID: 26860802
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
    Jiang Y, Liu FF, Cai YQ, Zhang P, Yang XF, Bi XY, Qin RY, Zhang S, Yin JH, Shen LP, Liu JX, Liu LS.
    Integr Cancer Ther; 2024 Feb; 23():15347354241268271. PubMed ID: 39081216
    [Abstract] [Full Text] [Related]

  • 6. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
    Yao J, Jiao L, Yao Y, Lu Y, Shi J, Li J, Chen P, Xu L, Gong Y.
    Trials; 2020 Apr 03; 21(1):309. PubMed ID: 32245480
    [Abstract] [Full Text] [Related]

  • 7. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, Chen JY, Niu XW, Su BR, Lu J, Wang ST.
    Ai Zheng; 2005 Oct 03; 24(10):1252-6. PubMed ID: 16219143
    [Abstract] [Full Text] [Related]

  • 8. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 9. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial.
    Chen Y, Yu M, Liu Z, Zhang Y, Li Q, Yang G.
    Trials; 2021 Jul 08; 22(1):437. PubMed ID: 34238342
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 08; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.
    Xue D, Han S, Jiang S, Sun H, Chen Y, Li Y, Wang W, Feng Y, Wang K, Li P.
    Med Oncol; 2015 Apr 08; 32(4):114. PubMed ID: 25772512
    [Abstract] [Full Text] [Related]

  • 13. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
    Chen W, Lin J, Yang T, Xin Zhang Z, Tao L, Xiao Z, Chen H, Qi X, Sun L, Cao Y, Lin L.
    Integr Cancer Ther; 2023 Apr 08; 22():15347354221151147. PubMed ID: 36710490
    [Abstract] [Full Text] [Related]

  • 14. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P, EORTC-LCG.
    Eur J Cancer; 2015 Aug 08; 51(12):1511-28. PubMed ID: 26074395
    [Abstract] [Full Text] [Related]

  • 15. [Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis].
    Jiang Y, Wu LB, Shen LP, Zhang P, Jiang WJ, Tian JH, Liu LS.
    Zhonghua Zhong Liu Za Zhi; 2016 Oct 23; 38(10):757-762. PubMed ID: 27784460
    [Abstract] [Full Text] [Related]

  • 16. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
    Gao R, Zhang Y, Hou W, Li J, Zhu G, Zhang X, Xu B, Wu Z, Wang H.
    Trials; 2021 Mar 17; 22(1):214. PubMed ID: 33731199
    [Abstract] [Full Text] [Related]

  • 17. [Effect of Chinese medicine comprehensive regimen as the maintenance therapy on time to progression and quality of life of patients with advanced non-small-cell lung cancer].
    Jiang Y, Liu LS, Li CJ.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Oct 17; 31(10):1311-6. PubMed ID: 22097195
    [Abstract] [Full Text] [Related]

  • 18. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY.
    J Clin Oncol; 2015 Jul 01; 33(19):2197-204. PubMed ID: 26014294
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
    Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L.
    J Clin Oncol; 2010 Jan 01; 28(1):49-55. PubMed ID: 19917841
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, EORTC Lung Cancer Group and the Italian Lung Cancer Project.
    Eur J Cancer; 2011 Oct 01; 47(15):2331-40. PubMed ID: 21802939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.